참고문헌
- Caggiano V, Weiss RV, Rickert TS, et al (2005). Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer, 103, 1916-24. https://doi.org/10.1002/cncr.20983
- Crawford J, Dale DC, Lyman GH (2004). Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer, 100, 228-37. https://doi.org/10.1002/cncr.11882
- Kuderer NM, Dale DC, Crawford J, et al (2006). Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer, 106, 2258-66. https://doi.org/10.1002/cncr.21847
- Kozma CDM, Chia V, Legg L, et al (2012). Trends in Neutropenia-Related Inpatient Events. J Oncol Pract, 8 (3):149-55. https://doi.org/10.1200/JOP.2011.000360
-
Liu J, Huang XE, Tian GY, et al (2013). Phase II Study on safety and efficacy of Yadanzi
$^{(R)}$ (Javanica oil emulsion injection) combined with chemotherapy for patients with gastric cancer. Asian Pac J Cancer Prev, 14, 2009-12. https://doi.org/10.7314/APJCP.2013.14.3.2009 - Lyman GH, Kuderer N, Greene J, Balducci L (1998). The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer, 34, 1857-64. https://doi.org/10.1016/S0959-8049(98)00222-6
- Lyman GH, Kuderer NM (2002). Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs, 62, 65-78. https://doi.org/10.2165/00003495-200262001-00005
- Lyman GH, Lyman CH, Agboola O (2005). Risk models for predicting chemotherapy-induced neutropenia. Oncologist, 10, 427-37. https://doi.org/10.1634/theoncologist.10-6-427
- Miller AB, Hoogstraten B, Staquet M, et al (1981). Reporting results of cancer treatment. Cancer, 47, 207-14. https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
- Morrison VA, Wong M, Hershman D, et al (2007). Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm, 13, 337-48.
- NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors.
- Schilling MBPC, Deeter RG (2011). Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Exp Ther Med, 2, 859-66.
- Tan HTK, Hurley D, Daniel G, et al (2011). Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin, 27, 79-6. https://doi.org/10.1185/03007995.2010.536527
- Weycker D, Malin J, Glass A, et al (2007). Economic burden of chemotherapy-related febrile neutropenia. J Support Oncol, 5, 44-5.
- Weycker DMJ, Barron R, Edelsberg J, et al (2011). Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol, 35, 267-74.
- Yan HA, Shen K, Huang XE (2013). Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4801-4. https://doi.org/10.7314/APJCP.2013.14.8.4801
-
Zhan YP, Huang XE, Cao J, et al (2012). Clinical study on safety and efficacy of Qinin
$^{(R)}$ (Cantharidin Sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev, 13, 4773-6. https://doi.org/10.7314/APJCP.2012.13.9.4773
피인용 문헌
- Clinical Study on Safety and Efficacy of JiSaiXin (Recombinant Human Granulocyte Colony Stimulating Factor Injection Manufactured in China) for Chinese Undergoing Chemotherapy vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.299
- Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6765
- Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.647
- Clinical Investigation in Effect of Riboflavin Sodium Phosphate on Prevention and Treatment for Patients with Radiotherapy Related Esophagitis vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1525
- Clinical Application of Serum Tumor Abnormal Protein (TAP) in Colorectal Cancer Patients vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3425
- Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
- A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485
- Effect of Peripheral Blood CD4 + CD25 + Regulatory T Cell on Postoperative Immunotherapy for Patients with Renal Carcinoma vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2027